Form 8-K

Send us Feedback

Endo Pharmaceuticals Holdings (ENDP)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

Annual Reports

Quarterly Reports

8-K

8-K (Feb 20, 2013)8-K (Jan 7, 2013)8-K (Jan 4, 2013)8-K (Dec 14, 2012)8-K (Dec 3, 2012)8-K (Nov 15, 2012)8-K (Nov 5, 2012)8-K (Oct 23, 2012)8-K (Oct 5, 2012)8-K (Oct 4, 2012)8-K (Sep 28, 2012)8-K (Sep 27, 2012)8-K (Aug 24, 2012)8-K (Aug 7, 2012)8-K (May 29, 2012)8-K (May 25, 2012)8-K (May 23, 2012)8-K (May 16, 2012)8-K (May 1, 2012)8-K (Mar 7, 2012)8-K (Feb 29, 2012)8-K (Feb 27, 2012)8-K (Feb 24, 2012)8-K (Jan 9, 2012)8-K (Dec 30, 2011)8-K (Dec 15, 2011)8-K (Dec 1, 2011)8-K (Nov 14, 2011)8-K (Nov 10, 2011)8-K (Oct 27, 2011)8-K (Oct 14, 2011)8-K (Oct 13, 2011)8-K (Oct 6, 2011)8-K (Oct 3, 2011)8-K (Sep 27, 2011)8-K (Sep 21, 2011)8-K (Aug 31, 2011)8-K (Aug 9, 2011)8-K (Jul 8, 2011)8-K (Jun 30, 2011)8-K (Jun 24, 2011)8-K (Jun 20, 2011)8-K (Jun 9, 2011)8-K (Jun 7, 2011)8-K (Jun 6, 2011)8-K (Jun 3, 2011)8-K (May 31, 2011)8-K (May 27, 2011)8-K (May 25, 2011)8-K (May 11, 2011)8-K (Apr 28, 2011)8-K (Apr 14, 2011)8-K (Apr 11, 2011)8-K (Mar 15, 2011)8-K (Mar 7, 2011)8-K (Mar 4, 2011)8-K (Mar 2, 2011)8-K (Mar 1, 2011)8-K (Feb 28, 2011)8-K (Feb 14, 2011)8-K (Jan 13, 2011)8-K (Jan 10, 2011)8-K (Jan 3, 2011)8-K (Dec 2, 2010)8-K (Dec 1, 2010)8-K (Nov 24, 2010)8-K (Nov 19, 2010)8-K (Nov 15, 2010)8-K (Nov 10, 2010)8-K (Nov 5, 2010)8-K (Nov 1, 2010)8-K (Oct 6, 2010)8-K (Oct 1, 2010)8-K (Sep 30, 2010)8-K (Sep 28, 2010)8-K (Sep 20, 2010)8-K (Aug 13, 2010)8-K (Aug 12, 2010)8-K (Jul 30, 2010)8-K (Jul 2, 2010)8-K (Jun 14, 2010)8-K (Jun 10, 2010)8-K (May 27, 2010)8-K (May 26, 2010)8-K (May 21, 2010)8-K (May 12, 2010)8-K (May 7, 2010)8-K (May 6, 2010)8-K (Apr 30, 2010)8-K (Apr 28, 2010)8-K (Mar 23, 2010)8-K (Mar 12, 2010)8-K (Mar 9, 2010)8-K (Feb 22, 2010)8-K (Jan 19, 2010)8-K (Jan 13, 2010)8-K (Jan 11, 2010)8-K (Dec 7, 2009)8-K (Nov 13, 2009)8-K (Nov 4, 2009)8-K (Oct 29, 2009)8-K (Oct 22, 2009)8-K (Oct 5, 2009)8-K (Sep 10, 2009)8-K (Aug 31, 2009)8-K (Aug 17, 2009)8-K (Jul 30, 2009)8-K (May 14, 2009)8-K (May 13, 2009)8-K (May 11, 2009)8-K (May 8, 2009)8-K (Apr 29, 2009)8-K (Apr 7, 2009)8-K (Apr 6, 2009)8-K (Apr 3, 2009)8-K (Mar 25, 2009)8-K (Mar 23, 2009)8-K (Mar 17, 2009)8-K (Feb 27, 2009)8-K (Feb 24, 2009)8-K (Feb 6, 2009)8-K (Jan 14, 2009)8-K (Jan 7, 2009)8-K (Jan 5, 2009)8-K (Dec 2, 2008)8-K (Nov 14, 2008)8-K (Oct 30, 2008)8-K (Sep 8, 2008)8-K (Jul 31, 2008)8-K (Jul 22, 2008)8-K (Jun 26, 2008)8-K (May 21, 2008)8-K (May 1, 2008)8-K (Apr 30, 2008)8-K (Apr 15, 2008)8-K (Apr 11, 2008)8-K (Apr 10, 2008)8-K (Apr 9, 2008)8-K (Apr 8, 2008)8-K (Mar 31, 2008)8-K (Mar 25, 2008)8-K (Mar 12, 2008)8-K (Mar 10, 2008)8-K (Mar 5, 2008)8-K (Mar 3, 2008)8-K (Feb 22, 2008)8-K (Jan 30, 2008)8-K (Jan 9, 2008)8-K (Dec 19, 2007)8-K (Dec 6, 2007)8-K (Nov 28, 2007)8-K (Nov 1, 2007)8-K (Sep 26, 2007)8-K (Sep 11, 2007)8-K (Aug 2, 2007)8-K (Aug 1, 2007)8-K (Jul 27, 2007)8-K (Jul 12, 2007)8-K (Jun 27, 2007)8-K (Jun 13, 2007)8-K (Jun 6, 2007)8-K (May 31, 2007)8-K (May 30, 2007)8-K (May 10, 2007)8-K (May 9, 2007)8-K (May 8, 2007)8-K (Apr 30, 2007)8-K (Apr 27, 2007)8-K (Apr 10, 2007)8-K (Mar 20, 2007)8-K (Mar 14, 2007)8-K (Mar 6, 2007)8-K (Feb 27, 2007)8-K (Feb 22, 2007)8-K (Feb 16, 2007)8-K (Jan 31, 2007)8-K (Jan 11, 2007)8-K (Jan 9, 2007)8-K (Jan 5, 2007)8-K (Dec 11, 2006)8-K (Nov 29, 2006)8-K (Nov 16, 2006)8-K (Nov 7, 2006)8-K (Oct 19, 2006)8-K (Sep 26, 2006)8-K (Sep 12, 2006)8-K (Aug 29, 2006)8-K (Aug 11, 2006)8-K (Aug 10, 2006)8-K (Aug 1, 2006)8-K (Jul 20, 2006)8-K (Jun 28, 2006)8-K (Jun 27, 2006)8-K (Jun 14, 2006)8-K (Jun 13, 2006)8-K (May 31, 2006)8-K (May 30, 2006)8-K (May 9, 2006)8-K (May 2, 2006)8-K (Apr 24, 2006)8-K (Apr 21, 2006)8-K (Apr 20, 2006)8-K (Apr 14, 2006)8-K (Mar 23, 2006)8-K (Mar 22, 2006)8-K (Mar 16, 2006)8-K (Mar 15, 2006)8-K (Mar 9, 2006)8-K (Mar 8, 2006)8-K (Feb 28, 2006)8-K (Feb 15, 2006)8-K (Feb 7, 2006)8-K (Jan 25, 2006)8-K (Jan 23, 2006)8-K (Jan 19, 2006)8-K (Jan 11, 2006)8-K (Jan 9, 2006)8-K (Dec 29, 2005)8-K (Dec 21, 2005)8-K (Nov 17, 2005)8-K (Nov 8, 2005)8-K (Oct 26, 2005)8-K (Oct 20, 2005)8-K (Oct 13, 2005)8-K (Oct 7, 2005)8-K (Oct 3, 2005)8-K (Sep 28, 2005)8-K (Sep 22, 2005)8-K (Sep 13, 2005)8-K (Jul 28, 2005)8-K (Jul 21, 2005)8-K (Jul 8, 2005)8-K (Jun 15, 2005)8-K (Jun 7, 2005)8-K (Jun 2, 2005)8-K (May 24, 2005)8-K (May 23, 2005)8-K (May 19, 2005)8-K (May 17, 2005)8-K (May 10, 2005)8-K (May 9, 2005)8-K (May 3, 2005)8-K (Apr 21, 2005)8-K (Apr 4, 2005)8-K (Mar 29, 2005)8-K (Mar 15, 2005)8-K (Mar 11, 2005)8-K (Feb 18, 2005)8-K (Feb 10, 2005)8-K (Jan 24, 2005)8-K (Jan 11, 2005)8-K (Nov 30, 2004)8-K (Nov 29, 2004)8-K (Nov 15, 2004)8-K (Nov 8, 2004)8-K (Oct 27, 2004)8-K (Oct 14, 2004)8-K (Sep 29, 2004)8-K (Sep 14, 2004)8-K (Aug 9, 2004)8-K (Jul 19, 2004)8-K (Jul 16, 2004)8-K (Jul 15, 2004)8-K (Jul 7, 2004)8-K (Jun 23, 2004)8-K (Jun 9, 2004)8-K (Jun 2, 2004)8-K (May 26, 2004)8-K (May 24, 2004)8-K (May 19, 2004)8-K (May 13, 2004)8-K (May 12, 2004)8-K (May 5, 2004)8-K (Apr 27, 2004)8-K (Apr 21, 2004)8-K (Apr 7, 2004)8-K (Mar 24, 2004)8-K (Mar 10, 2004)8-K (Mar 9, 2004)8-K (Feb 24, 2004)8-K (Feb 5, 2004)8-K (Jan 13, 2004)8-K (Jan 5, 2004)8-K (Nov 12, 2003)8-K (Oct 23, 2003)8-K (Jul 24, 2003)8-K (Jun 16, 2003)8-K (Apr 30, 2003)8-K (Apr 24, 2003)8-K (Apr 10, 2003)8-K (Mar 25, 2003)8-K (Mar 20, 2003)8-K (Mar 19, 2003)8-K (Mar 5, 2003)8-K (Feb 25, 2003)8-K (Feb 20, 2003)8-K (Feb 13, 2003)8-K (Jan 15, 2003)8-K (Jan 6, 2003)8-K (Dec 30, 2002)8-K (Dec 20, 2002)8-K (Nov 14, 2002)8-K (Oct 28, 2002)8-K (Oct 24, 2002)8-K (Sep 17, 2002)8-K (Aug 28, 2002)8-K (Aug 23, 2002)8-K (Aug 1, 2002)8-K (Jul 31, 2002)8-K (Jul 25, 2002)8-K (Jun 25, 2002)8-K (Jun 24, 2002)8-K (May 1, 2002)8-K (Apr 25, 2002)8-K (Mar 6, 2002)8-K (Feb 21, 2002)8-K (Jan 17, 2002)8-K (Jan 8, 2002)8-K (Dec 17, 2001)8-K (Dec 6, 2001)8-K (Nov 27, 2001)8-K (Nov 20, 2001)8-K (Nov 16, 2001)8-K (Nov 13, 2001)8-K (Oct 18, 2001)8-K (Sep 10, 2001)8-K (Sep 5, 2001)8-K (Aug 31, 2001)8-K (May 14, 2001)8-K (Mar 23, 2001)8-K (Mar 15, 2001)8-K (Oct 25, 2000)8-K (Oct 11, 2000)8-K (Jul 24, 2000)

Other

ENDO HEALTH SOLUTIONS INC. 8-K 2012

Documents found in this filing:

Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 27, 2012 (February 27, 2012)

Endo Pharmaceuticals Holdings Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-15989	13-4022871
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

100 Endo Boulevard, Chadds Ford, PA		19317
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (610) 558-9800

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01

Regulation FD Disclosure.

On February 27, 2012, the Registrant intends to make a slide presentation at the Citi Global Health Care Conference, a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

This slide presentation includes financial measures that are not in conformity with accounting principles generally accepted in the United States. We refer to these as non-GAAP financial measures. Specifically, the presentation refers to adjusted diluted earnings per share.

The adjusted diluted earnings per share are non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with accounting principles generally accepted in the United States and may be different from non-GAAP financial measures used by other companies. Endo refers to these non-GAAP financial measures in making operating decisions because it believes they provide meaningful supplemental information regarding the company’s operational performance. For instance, Endo believes that these non-GAAP financial measures facilitate its internal comparisons to its historical operating results and comparisons to competitors’ results. The company includes these non-GAAP financial measures because it believes they are useful to investors in allowing for greater transparency related to supplemental information used by Endo in its financial and operational decision-making. In addition, Endo has historically reported similar non-GAAP financial measures to its investors and believes that the inclusion of comparative numbers provides consistency in its financial reporting at this time. Further, Endo believes that these non-GAAP financial measures may be useful to investors as it is aware that certain of its significant stockholders utilize these measures to evaluate its financial performance. Finally, these measures are considered by the Compensation Committee of Endo’s Board of Directors in assessing the performance and compensation of substantially all of its employees, including its executive officers. Investors are encouraged to review the reconciliation of the non-GAAP financial measures used in this presentation to their most directly comparable GAAP financial measures as provided in this slide presentation.

Item 9.01.

Financial Statements and Exhibits.

(d)	Exhibits.


Exhibit Number		Description

99.1		Slide Presentation of Endo Pharmaceuticals Holdings Inc. dated February 27, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


ENDO PHARMACEUTICALS HOLDINGS INC.
(Registrant)

By:		/s/ CAROLINE B. MANOGUE
Name:		Caroline B. Manogue
Title:		Executive Vice President, Chief Legal Officer & Secretary

Dated: February 27, 2012

INDEX TO EXHIBITS


Exhibit Number		Description

99.1		Slide Presentation of Endo Pharmaceuticals Holdings Inc. dated February 27, 2012

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

Endo Pharmaceuticals Holdings (ENDP)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing: